December 2024 in “Pharmaceutics” Extracellular vesicles show promise for treating psoriasis by reducing inflammation and skin lesions.
August 2024 in “Drug Design Development and Therapy” Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
November 2023 in “ACS Omega” New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
April 2023 in “Clinical Chemistry and Laboratory Medicine” The document concludes that inflammation markers can be used in diabetes, vitamin D3 affects immune pathways, hyperthyroidism changes hormone levels, androgen levels help diagnose Adrenocortical Carcinoma, erectile dysfunction is linked to diabetes, hypogonadism is common in HIV-infected males, and hormones can be biomarkers for various conditions.
February 2023 in “IntechOpen eBooks” Testosterone replacement therapy helps manage deficiency and has various methods, but requires careful monitoring to avoid side effects.
August 2022 in “IARS international research journal” The document concludes that drug repurposing, which is reusing known medicines for new illnesses, can provide faster, cheaper treatment options for various serious diseases, including cancer, COVID-19, and rare diseases.
October 2022 in “Biomedicines” Finasteride in male rats causes liver and metabolic issues in their offspring.
September 2022 in “Dermatology and therapy” Androgenetic alopecia is linked to heart disease, metabolic issues, and mental health problems.
January 2022 in “Springer eBooks”
March 2024 in “Journal of Pharmaceutical and Sciences” Zaleya pentandra extracts, especially acetone, may be useful for new medicines and food industry applications.
24 citations,
June 2011 in “Andrologia” Ganoderma lucidum may help treat enlarged prostate in rats.
19 citations,
March 2018 in “Expert Opinion on Drug Safety” Most treatments for spondyloarthritis are safe, but monitoring and careful selection based on patient risks are important.
1 citations,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
213 citations,
June 2017 in “Rheumatology” The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
17 citations,
August 2015 in “Expert Opinion on Pharmacotherapy” The document concludes that oral finasteride and topical minoxidil are effective for genetic hair loss, while other treatments for different types of hair loss show promise but need more research.
12 citations,
October 2013 in “The Prostate” Dutasteride and finasteride affect different cell types differently.
12 citations,
January 1998 in “Endocrine journal” Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.
Custom skincare can be made based on genes, fewer cats in Lublin have FeLV/FIV than national average, and studies also looked at small water bodies, river pollution, guppy growth, toxins in biochars, palm oil issues, and pumpkin seed oil for hair strength.
60 citations,
January 2004 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying a specific inhibitor lightens skin and hair color.
41 citations,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
16 citations,
January 2000 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.
6 citations,
July 2016 in “Gynecological Endocrinology” PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.
5 citations,
January 2010 in “Acta Chirurgica Iugoslavica” Higher urethral PSA levels after prostate removal may be linked to more scalp hair loss and more PSA in urethral glands.
3 citations,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
1 citations,
October 2006 in “Oncology times” Finasteride improves prostate cancer detection in PSA test.
September 2009 in “European Urology Supplements” After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
March 2009 in “The Journal of Urology” Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.
June 2007 in “Nature Clinical Practice Urology” Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.
April 2007 in “Nature Clinical Practice Urology” Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.
April 2012 in “The Journal of Urology” PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.